Thank you for registering your interest in our triple-negative breast cancer study. A member of the research team will be in touch within 2 business days to go through the study with you.
What is the study for?
The purpose of this research is to evaluate Magrolimab in combination with either nab-paclitaxel or paclitaxel for the treatment of metastatic triple-negative breast cancer (mTNBC) for patients with untreated mTNBC.
This study is split into two parts. The initial phase (safety run-in) is to confirm a safe dose of magrolimab in combination with either nab-paclitaxel or paclitaxel, and the second part (phase 2) is to see if magrolimab in combination with nab-paclitaxel or paclitaxel is effective in treating mTNBC.
For participants considered for the study, you will attend the clinic for a screening visit.
Study treatment will be given in 28-day (4 week) cycles. You will be required to visit the clinic the following number of times while on treatment:
- Cycle 1: 5 times
- Cycle 2: 4 times
- Cycle 3: 3 times
- Approximately every 8 weeks until you stop study treatment
This is a phase 2 open-label study. Open-label means you and your study doctor will know what study drug(s) you will be taking. Your study doctor will inform you if you are assigned to the Safety Run-in, or in the Randomized Phase 2 (Arm A or Arm B) part of the study.
The research team will sit down with you and go through the study criteria, as well as your medical history, current and past medications and vaccinations. There will be some blood tests and medical examinations to help determine your eligibility for the study.
You will be required to present a valid form of ID at each visit.
All study procedures are at no cost to you, and you will be reimbursed for your time and travel expenses.
Where can I find more information?
More information can be requested by contacting the research site to the right. Alternatively, the research team will be more than happy to answer any questions you may have when they call.
You can also find more study information on the clinical trials database, ClinicalTrials.gov
HREC approval: Bellberry Human Research Ethics Committee